Novel Agents for the Prevention of Leishmaniosis

Information

  • Patent Application
  • 20080026467
  • Publication Number
    20080026467
  • Date Filed
    November 19, 2004
    20 years ago
  • Date Published
    January 31, 2008
    16 years ago
Abstract
The invention relates to nucleic acid constructions, characterized in that they comprise nucleic acids which are isolated in the sense position and which are capable of coding for an immunogenic protein of promastigotes or amastigotes of Leishmania, said nucleic acids responding to one of the sequences SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5 et SEQ ID No. 11 and coding for a protein respectively exhibiting a sequence SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10 et SEQ ID No. 12. The invention can be used for over-expression of the genes of Leishmania coding for an excretion/secretion antigen.
Description

Other characteristics and advantages of the invention will be given in the examples which follow, in which reference will be made to FIGS. 1 to 8, which represent, respectively:



FIG. 1, the 3′ alignment of the nucleotide sequences of cDNA clones according to the invention;



FIG. 2, a recapitulative diagram of the nucleotide sequences of the cDNA clones obtained after immunoscreening, with an anti-ESA monoclonal antibody, of L. amazonensis promastigote form and amastigote form expression libraries. The restriction enzyme sites are indicated above each sequence;



FIG. 3A, the location of various protein regions, characterized by their specific amino acid composition, present on the protein sequence deduced from the cDNA of the clone A3B; and



FIG. 3B, a diagrammatic representation of the protein sequence deduced from the cDNA of the clone A3B encoding a PSA;



FIG. 4, the analyses of the transcripts by RT-PCR in the promastigote (P) and amastigote (A) forms;



FIG. 5, the level of production of the protein by Western blotting, using an anti-PSA antibody;



FIG. 6, the effect of the overexpression of a PSA of L. amazonensis on the infectious capacity of the parasites;



FIG. 7, the nucleotide sequences SEQ ID Nos 1 to 5 and 11, respectively, of the clones A3B, 2C1, 1A1, 2G1 and W2 of L. amazonensis promastigotes and amastigotes and IJ11 of L. infantum promastigotes, and the corresponding encoded amino acid sequences SEQ ID Nos 6 to 10 and 12, and



FIG. 8, the parasitic index determined during the in vitro infection of canine macrophages with a wild-type strain or selected L. infantum promastigote clones, at various incubation times.





1-MOLECULAR CHARACTERIZATION OF THE MAJOR IMMUNOGENS OF THE ESAs OF PROMASTIGOTE AND AMASTIGOTE FORMS OF L. amazonensis (ABBREVIATED TO Lma)

This characterization was carried out by screening L. amazonensis promastigote form and amastigote form cDNA expression libraries using a monoclonal antibody directed against the ESA major immunogen.


cDNA Library Characteristics:


Two cDNA expression libraries, respectively of promastigote forms and of amastigote forms of L. amazonensis, were produced. The characteristics of these libraries are given in table I. The exponential-phase and stationary-phase parasites were mixed in order to have access to the various transcripts that may be expressed during the various stages of the in vitro culturing thereof. 5×104 phages per library were then immunoscreened with the monoclonal antibody F5 diluted to 1/500. The production of this antibody is the subject of the example in the FR patent mentioned above.













TABLE I







cDNA library Lma LES





D4 + D7
Promastigotes
Amastigotes









Harvest D4 + D7
7.8 · 109
7.8 · 109



Titration after packaging
350 000
500 000



Titer after amplification
8.32 · 107 pH/ul
2.16 · 108 pH/ul







D4 + D7 = parasites harvested on the 4th day, in the exponential phase, and on the 7th day, in the stationary phase of their growth.






Isolation and Sequencing of the Clones Recognized by the Monoclonal Antibody F5


13 clones of the promastigote library were found to be positive and 11 clones of the amastigote library were found to be positive. All these clones were isolated by secondary and tertiary screening.


The plasmid DNA of all the clones isolated was analyzed after various enzymatic digestions and the cDNAs having larger inserts, by EcoRI/XhoI digestion, were selected in order to eliminate the cDNAs that were too truncated in the 5′ position. As shown in table II, the clones 1A1, 1B1, 2B3, 2C1, 2D1 and 2E1 of the promastigote cDNA library and the clones A3B, V4A, V5, W2 and W3 of the amastigote library exhibit the larger inserts.


The analysis of these clones, by determining the presence or absence of two previously selected restriction enzyme sites (HindIII and SalI), show that they exhibit strong homology of their nucleotide sequence.


Three different classes of clones were demonstrated, by double HindIII/SalI digestion, with a HindIII/SalI fragment less than 400 bp in size (clone 2G1), 500 bp in size (clones of type 2C1 and A3B) or 600 bp in size (clones of type 1A1 or W2), respectively. Thus, five types of clones, chosen according to the specific characteristics of their DNA (the size of the insert and the location of certain restriction enzyme sites) are represented in bold characters in table II.









TABLE II







Lma promastigote cDNA library









cDNA clones






















1A1

1B1
1C1
1D5
1F1
2A2
2B3
2C1
2D1
2E1
2F1

2G1

B3A





Size of the

2.5

2.5
2-2.2
0.5
2  
2 (>)
2.5
2.4
2.4
2.4
2

1.7-2

1.7


EcoRI/XhoI


inserts


(kb)


Restriction


map


SalI
Y
Y
Y
N
N
N
Y
Y
Y
Y
N
Y
N


HindIII
1.1
1.1
1.1
/
1.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1


HindIII/SalI

600

600
500
N
N
N
600
500
500
500
N

<400

N


(bp)


Recombinant


protein


expression


(kDa)

45

/
40
/
/
/
/
42.5
/
/
39
?
18










Lma amastigote cDNA library









cDNA clones




















A3B

V1B
V2D
V3A
V4A
V5
W1A
W1C

W2

W3
W5





EcoRI/XhoI

2.3

2-2.2
2.2
?
2.3
2.3
2
2

2.3

2.2
1.7


(kb)


Restriction


map


SalI
Y
Y
Y
N
Y
Y
N
N
Y
Y
N


HindIII
1.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1


HindIII/SalI

505

500
500
N
500
500
N
N

600

500<  
N


(bp)


Recombinant


Protein


expression


(kDa)

42.5

/
36.5
/
36.5
43
/
/

45

/
/





Y = yes, for site present;


N = no, for site absent;


/ = performed;


? = result not obtained.






Table II also gives the results relating to the ability of the clones to express a recombinant protein. IPTG was used as an inducing agent. The samples were analyzed by SDS-PAGE and immunoblotting in the presence of the antibody against promastigote form and/or amastigote form ESA, preabsorbed in the presence of E. coli lysate. Equivalent results are obtained. For clones of interest, the expression of various recombinant proteins ranging from 42.5 kDa in apparent molecular weight (clone 2C1), to 43 kDa (clone A3B) or 45 kDa (1A1 and W2) is noted.


The “sequence listing” document reports the results of the sequencing:

    • of the following three types of clones of the promastigote library:
    • the clone of type 1A1 (SEQ ID No 3), which expresses a protein, of sequence SEQ ID No 8, of higher molecular weight. The clones of type 1B1 and 2B3 are of the same type as this clone;
    • the clone 2C1 (SEQ ID No 2), which expresses a recombinant protein of molecular weight lower than that of the clone 1A1, having a sequence SEQ ID No 7;
    • the clone 2G1 (SEQ ID No 4), which has the particularity of possessing a small HindIII/SalI fragment, which expresses a recombinant protein of molecular weight lower than that of the clone 1A1, having a sequence SEQ ID No 9;
    • of the following two clones of the amastigote library:
    • the clones of type A3B (SEQ ID No 1), which express a recombinant protein of approximately 43 kDa, of sequence SEQ ID No 6 and having a 500 bp HindIII/SalI fragment, the clone V5 appearing to be identical. The clones V2D and V4A are considered to be truncated clones of the same type;
    • the clone W2 (SEQ ID No 5), which expresses a recombinant protein of 45 kDa, of sequence SEQ ID No 10 and which has a 600 bp HindIII/SalI fragment.


Study of the Five cDNA Sequences


The alignment of the five cDNA sequences obtained is represented in FIG. 1, where the differences between these clones are only due to the presence of a 5′-truncated sequence and/or the insertion of sequences of approximately 72 nucleotides of the 5′ side. The clones thus exhibit one (clones 2C1 and A3B) or three (clones 1A1 and W2) insertions. Outside these insertion zones, the clones exhibit homologies of the order of 99% and can be considered to belong to a cDNA family. Only the clone A3B has the ATG initiation codon, the other clones being 5′-truncated. However, the A3B cDNA does not have the 39 nt sequence encoding the “splice leader” found in the 5′ position on all Leishmania mRNAs.


The cDNAs of the clones A3B and 2C1 exhibit virtually total homology and are therefore considered to be identical, the cDNA of the clone 2C1 corresponding to a 5′-truncated portion of the cDNA of the clone A3B.


The clone A3B, representative of this family, was the subject of complete sequencing in both directions.


The restriction enzyme sites for each of these clones are reported in FIG. 2.


The sequences SEQ ID Nos 1 to 5 correspond, respectively, to those of the cDNAs of A3B, 2C1, 1A1, 2G1 and W2.


Analysis of the Various Deduced Protein Sequences


The translation of the various cDNA sequences into protein sequences was carried out by choosing the reading frame corresponding to that suggested by the position of the initiation codon on the plasmid pB-SK, the transcription of which is under the control of the promoter of the lacZ gene subjected to induction with IPTG.


The A3B protein exhibits the regions illustrated in FIGS. 3A and 3B. At the NH2-terminal, a hydrophobic peptide, which can be cleaved, and which is described in the literature as a secretion pathway signal peptide, is identified. This is followed by the leucine-rich repeat domain, the clone A3B possessing 6 repeats. About ten amino acids from the end of this domain is a region rich in proline, threonine and serine, hereinafter called poly P/T/S region. This region is followed by a cysteine-rich region, that can be involved in disulfide bridges. Finally, the protein sequence ends with a hydrophobic signal peptide.


The cDNAs of the clones A3B and 2C1 exhibit virtually total homology and are therefore considered to be identical, the cDNA of the clone 2C1 corresponding to a 5′-truncated portion of the cDNA of the clone A3B.


The clone A3B, representative of this family, was the subject of complete sequencing in both directions.


The restriction enzyme sites for each of these clones are reported in FIG. 2: Nt=nucleotides; ATG=initiation codon; TAG=stop codon.


Analysis on the PROSITE database shows that the A3B protein has an N-glycosylation site located at the end of each leucine-rich repeat domain, and 12 potential phosphorylation sites.


Analysis of the location of this protein on the PSORT server predicts a cytoplasmic location at 92%, which indicates that the protein is soluble. This protein is probably anchored to the surface via a glycosyl phosphatidyl inositol or GPI. The hydrophobic signal peptide can therefore be cleaved and allow anchoring of the GPI at the level of asparagine (D).


The theoretical molecular weight of the protein of the clone A3B differs by approximately 2.9 kDa from that of the 1A1 and W2 proteins, which is in agreement with the difference of 2.5 kDa observed between the corresponding recombinant proteins. This difference is due to the presence of a variable number of leucine-rich repeats or LRRs, each also exhibiting a specific amino acid composition.


The apparent and theoretical molecular weights of the four types of PSA of the invention are given in table III below.












TABLE III






MW of the

MW without



recombinant
Theoretical MW
signal peptide


Type of PSA
protein
(nontruncated)
(3.2 kDa)







4 LRR (2G1)
/
33.5 kDa
30.3 kDa


6 LRR (A3B)
42.5 kDa
38.5 kDa
35.3 kDa


7 LRR (1A1 and W2)
  45 kDa
41.4 kDa
38.2 kDa









2-Obtaining Genetically Modified Parasites:

Directional cloning of the LaPSA 38s gene into the expression vector pTex made it possible to obtain a construct capable of expressing the PSA gene in the sense position. The plasmid pTex-LaPSA 38s sense orientation and the empty vector pTex were then electroporated into the wild-type strain Leishmania infantum Mon 1 Clone 1, and the parasites were then selected with geneticin.


The study was carried out on wild-type (WT) parasites of the species L. infantum, those transfected with empty pTex (pTex) and those transfected with pTex containing the nucleotide sequence of interest (sense).


Molecular Characterization:


The analysis of the total DNA by Southern blotting shows that the sense construct is stable and amplified in the transformed strain. The results are given in FIG. 4, which gives the analyses of the transcripts by RT-PCR in the two forms, promastigotes (P) and amastigotes (A). FIG. 5 gives the level of production of the protein by Western blotting, using an anti-PSA. antibody (FIG. 5A: constitutive proteins; FIG. 5B: excreted/secreted proteins).


Phenotypic Characterization of the Mutants:


The comparison of the growth kinetics between Ldi WT, Ldi pTex and Ldi Sense shows that the overexpression of LaPSA 38s does not interfere with the growth of the parasites. Only a longer lag phase is observed for the strains transformed with the wild-type strain.


The sensitivity to lysis by human complement was also studied. Recently, it was demonstrated that L. amazonensis PSA had the property of inhibiting the action of complement in vitro. The “sense” promastigotes are more sensitive to complement. The excess PSA at the surface of the parasites can thus lead to cleavage and also to a greater formation of complexes engendering increased lysis.


Study of Infectious Capacity of the Parasites


To study the effect of the overexpression of LaPSA 38s on the infectious capacity of the parasites, the first approach consisted in bringing promastigotes of the transformed strains into contact with macrophages from dog, which is the natural domestic reservoir for visceral leishmaniasis.



FIGS. 6A and 6B give the results obtained, respectively, 2 h after contact with the promastigotes and 48 h after contact with the amastigotes; in these figures, the parasitic index corresponds to the % of macrophages infected with the Sense strain×the number of parasites per macrophage/% of macrophages infected with the control strain (pTex)×the number of parasites per macrophage.


The promastigotes overexpressing LaPSA 38s exhibit twice as much infectious capacity with respect to canine macrophages. Furthermore, after phagocytosis, the amastigotes expressing the transgene possess a capacity to survive and to multiply in the parasitophorous vacuole that is significantly greater (2.5 to 5 times) than that of the control transfected with the empty vector.


2-Molecular Characterization of the L. infantum Promastigote ESAs

The nucleotide sequence of the L. infantum promastigote clone IJ11 is given in FIG. 7 (SEQ ID No 11) along with the corresponding amino acid sequence (SEQ ID No 12).



FIG. 8 reports the parasitic index determined during the in vitro infection of canine macrophages with the wild-type strain or the various selected L. infantum promastigote form clones (MHON/MA/67/ITMAP-263, clone 2), at various incubation times. The examination of these results shows attachment of the parasites to the macrophages after 30 min, penetration of the parasites after 2 hours and survival and multiplication of the intracellular amastigotes at 48 hours.

Claims
  • 1. A nucleic acid construct, characterized in that it comprises an isolated nucleic acid in the sense position, capable of encoding an immunogenic protein of promastigote forms or of amastigote forms of Leishmania, said nucleic acid corresponding to one of the sequences SEQ ID No 1, SEQ ID No 2, SEQ ID No 3, SEQ ID No 4, SEQ ID No 5 and SEQ ID No 11.
  • 2. The construct as claimed in claim 1, characterized in that the sequence comprises a SalI restriction site and two HindIII restriction sites, with a stop codon located downstream of the first HindIII site.
  • 3. The construct as claimed in claim 2, characterized in that said nucleic acid sequence comprises an EcoRV and/or PstI restriction site between the two sites SalI and HindIII, or on either side of the SalI site.
  • 4. The construct as claimed in claim 1, characterized in that said nucleic acid sequence is cloned in the sense position into a plasmid such as pTex.
  • 5. The construct as claimed in claim 1, characterized in that it encodes an immunogenic protein of promastigote forms or of amastigote forms of Leishmania, these proteins corresponding to one of the sequences SEQ ID No 6, SEQ ID No 7, SEQ ID No 8, SEQ ID No 9, SEQ ID No 10 and SEQ ID No 12.
  • 6. An isolated immunogenic protein, characterized in that it has a sequence chosen from SEQ ID No 6, SEQ ID No 7, SEQ ID No 8, SEQ ID No 9, SEQ ID No 10 or SEQ ID No 12.
  • 7. A genetically modified Leishmania strain, characterized in that it corresponds to Leishmania amastigote or promastigote forms transfected with a construct as claimed in claim 1.
  • 8. The strain as claimed in claim 7, characterized in that it is an L. infantum strain.
  • 9. A method of transfecting a Leishmania parasite, characterized in that a construct as claimed in claim 1, comprising a marker, is introduced into the Leishmania parasite, the transfected parasites are selected by means of said marker, they are placed in culture in a completely defined axenic and serum-free medium, and the culture supernatant which contains the immunogenic proteins present in concentrations of the order of 10 to 20 times higher than that produced by the Leishmania mother strain is recovered.
Priority Claims (2)
Number Date Country Kind
0313555 Nov 2003 FR national
0407010 Jun 2004 FR national
PCT Information
Filing Document Filing Date Country Kind 371c Date
PCT/FR04/02955 11/19/2004 WO 00 2/16/2007